Journal of Assisted Reproduction and Genetics

, Volume 34, Issue 4, pp 471–478 | Cite as

Effect of GnRHa ovulation trigger dose on follicular fluid characteristics and granulosa cell gene expression profiles

  • Thi Ngoc Lan Vuong
  • M. T. Ho
  • T. Q. Ha
  • M. Brehm Jensen
  • C. Yding Andersen
  • P. Humaidan
Assisted Reproduction Technologies



A recent dose-finding study showed no significant differences in number of mature oocytes, embryos and top-quality embryos when triptorelin doses of 0.2, 0.3 or 0.4 mg were used to trigger final oocyte maturation in oocyte donors co-treated with a gonadotropin-releasing hormone (GnRH) antagonist. This analysis investigated whether triptorelin dosing for triggering final oocyte maturation in oocyte donors induced differences in follicular fluid (FF) hormone levels and granulosa cell gene expression.


This single-centre, randomised, parallel, investigator-blinded trial was conducted in oocyte donors undergoing a single stimulation cycle at IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam, from August 2014 to March 2015. A total of 165 women aged 18–35 years with body mass index <28 kg/m2, anti-Müllerian hormone >1.25 ng/mL, and antral follicle count ≥6 were randomised to three different triptorelin doses for trigger. The main outcome was concentration of steroid hormones in FF collected from the first punctured follicle on each side. Moreover, luteinising hormone receptor (LHR), 3β-hydroxy-steroid-dehydrogenase (3ßHSD) and inhibin-Ba (INHB-A) gene expression in cumulus and mural granulosa cells were investigated in a subset of women from each group.


Progesterone and oestradiol levels in FF did not differ significantly by trigger doses; findings were similar for 3βHSD, LHR and INHB-A gene expression in both cumulus and mural granulosa cells.


In women co-treated with a GnRH antagonist, no significant differences in FF steroid levels and granulosa cell gene expression were seen when different triptorelin doses were used to trigger final oocyte maturation.


In vitro fertilisation Gonadotropin-releasing hormone agonist trigger LHR gene expression Triptorelin Follicular fluid 



English language medical writing assistance was provided by Nicola Ryan, an independent medical writer.

Compliance with ethical standards


The study was supported by Merck Sharp and Dohme.

Competing interests

The authors state that they have no competing interests.

Ethics approval and informed consent

All patients provided written informed consent. The study protocol was approved by the Institutional Review Board (IRB) and Ethics Committee on 21 July 2014 (IRB reference number: NCKH/CGRH_01_2014).


  1. 1.
    Albano C, Smitz J, Camus M, Riethmuller-Winzen H, Van Steirteghem A, Devroey P. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril. 1997;67(5):917–22.CrossRefPubMedGoogle Scholar
  2. 2.
    Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod. 2000;15(7):1490–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod. 2000;15(9):1965–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Itskovitz-Eldor J, Kol S, Mannaerts B, Coelingh Bennink H. First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462). Hum Reprod. 1998;13(2):294–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Humaidan P, Kol S, Papanikolaou EG, Copenhagen GnRH Agonist Triggering Workshop Group. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update. 2011;17(4):510–24.CrossRefPubMedGoogle Scholar
  6. 6.
    Vuong TN, Ho MT, Ha TD, Phung HT, Huynh GB, Humaidan P. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study. Fertil Steril. 2016;105(2):356–63.CrossRefPubMedGoogle Scholar
  7. 7.
    Zamah AM, Hassis ME, Albertolle ME, Williams KE. Proteomic analysis of human follicular fluid from fertile women. Clin Proteomics. 2015;12(1):5.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lan VT, Linh NK, Tuong HM, Wong PC, Howles CM. Anti-Mullerian hormone versus antral follicle count for defining the starting dose of FSH. Reprod Biomed Online. 2013;27(4):390–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Smith AH, Bates MN. Confidence limit analyses should replace power calculations in the interpretation of epidemiologic studies. Epidemiology. 1992;3(5):449–52.CrossRefPubMedGoogle Scholar
  10. 10.
    Gonen Y, Balakier H, Powell W, Casper RF. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab. 1990;71(4):918–22.CrossRefPubMedGoogle Scholar
  11. 11.
    Hoff JD, Quigley ME, Yen SS. Hormonal dynamics at midcycle: a reevaluation. J Clin Endocrinol Metab. 1983;57(4):792–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Mattheij JA, Swarts HJ. Induction of luteinized unruptured follicles in the rat after injection of luteinizing hormone early in pro-oestrus. Eur J Endocrinol. 1995;132(1):91–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Saal W, Glowania HJ, Hengst W, Happ J. Pharmacodynamics and pharmacokinetics after subcutaneous and intramuscular injection of human chorionic gonadotropin. Fertil Steril. 1991;56(2):225–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Yding Andersen C, Westergaard LG, Figenschau Y, Bertheussen K, Forsdahl F. Endocrine composition of follicular fluid comparing human chorionic gonadotrophin to a gonadotrophin-releasing hormone agonist for ovulation induction. Hum Reprod. 1993;8(6):840–3.CrossRefPubMedGoogle Scholar
  15. 15.
    Andersen CY, Humaidan P, Ejdrup HB, Bungum L, Grondahl ML, Westergaard LG. Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction. Hum Reprod. 2006;21(8):2126–30.CrossRefPubMedGoogle Scholar
  16. 16.
    Humaidan P, Westergaard LG, Mikkelsen AL, Fukuda M, Yding Andersen C. Levels of the epidermal growth factor-like peptide amphiregulin in follicular fluid reflect the mode of triggering ovulation: a comparison between gonadotrophin-releasing hormone agonist and urinary human chorionic gonadotrophin. Fertil Steril. 2011;95(6):2034–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Humaidan P, Van Vaerenbergh I, Bourgain C, Alsbjerg B, Blockeel C, Schuit F, et al. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles. Hum Reprod. 2012;27(11):3259–72.CrossRefPubMedGoogle Scholar
  18. 18.
    Borgbo T, Povlsen BB, Andersen CY, Borup R, Humaidan P, Grondahl ML. Comparison of gene expression profiles in granulosa and cumulus cells after ovulation induction with either human chorionic gonadotropin or a gonadotropin-releasing hormone agonist trigger. Fertil Steril. 2013;100(4):994–1001.CrossRefPubMedGoogle Scholar
  19. 19.
    Humaidan P, Alsbjerg B. GnRHa trigger for final oocyte maturation: is HCG trigger history? Reprod Biomed Online. 2014;29(3):274–80.CrossRefPubMedGoogle Scholar
  20. 20.
    Humaidan P, Engmann L, Benadiva C. Luteal phase supplementation after gonadotropin-releasing hormone agonist trigger in fresh embryo transfer: the American versus European approaches. Fertil Steril. 2015;103(4):879–85.CrossRefPubMedGoogle Scholar
  21. 21.
    Humaidan P, Polyzos NP, Alsbjerg B, Erb K, Mikkelsen AL, Elbaek HO, et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod. 2013;28(9):2511–21.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Thi Ngoc Lan Vuong
    • 1
    • 2
  • M. T. Ho
    • 2
    • 3
  • T. Q. Ha
    • 2
  • M. Brehm Jensen
    • 4
  • C. Yding Andersen
    • 4
  • P. Humaidan
    • 5
    • 6
  1. 1.Department of Obstetrics and GynaecologyUniversity of Medicine and Pharmacy HCMCHo Chi Minh CityVietnam
  2. 2.IVFMDMy Duc HospitalHo Chi Minh CityVietnam
  3. 3.Research Center for Genetics and Reproductive Health (CGRH), School of MedicineVietnam National University HCMCHo Chi Minh CityVietnam
  4. 4.Laboratory of Reproductive Biology, The Copenhagen University Hospital and Faculty of Health ScienceCopenhagen UniversityCopenhagenDenmark
  5. 5.The Fertility ClinicSkive Regional HospitalSkiveDenmark
  6. 6.Faculty of Health, Aarhus University and Faculty of HealthUniversity of Southern DenmarkAarhusDenmark

Personalised recommendations